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Gained (LYG); Quality-Adjusted Life Years (QALY’s); long-term
costs; and cost-effectiveness for IDet vs. NPH. Standard
Markov/Monte Carlo simulation techniques were used to
describe incidence and progression of complications. Probabili-
ties of complications and HbA1c-dependent adjustments were
derived from the UKPDS and other major clinical trials and pop-
ulation studies. Clinical input was taken from a 6-month multi-
centre, multinational, open-label, parallel-group comparison
phase III trial in type-2 patients. Costs of treating complications
in the UK and utility values were retrieved from published
sources. Direct costs of diabetes complications and drug treat-
ment were projected over patients’ lifetimes from a UK National
Health Service perspective. RESULTS: The model projected that
treatment with IDet would result in an extra 0.13 LYG and 0.08
QALYs per patient. Total lifetime costs/patient were estimated to
increase by £1534. The cost per LYG was calculated to be 11,700
GBP and the cost per QALY to be £19,218. CONCLUSIONS:
The model predicted that treatment with IDet would result in
long term improvements in health outcomes and quality of life
compared to NPH in patients with type-2 diabetes. The cost-
effectiveness result is within the range considered to represent
value for money in the UK.
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OBJECTIVES: To examine the diabedic type-2 cost predictors.
METHODS: A total of 303 patients diagnosed with type-2 dia-
betes mellitus (mean age: 61, mean time from diagnosis: 10.86
year, males: 49%), were randomly selected from out-patients
charts databases and surveyed. Both patient and practitioner
questionnaires collected data from each patient on: clinical char-
acteristic, medical and other resources used, quality of life. Step-
wise linear regression model was elaborated to determine most
signiﬁcant clinical variables associated with cost. Values are
expressed in PLN (PLN1 = 0.4808€ PPP’2003). RESULTS: The
total annual treatment costs amounted to PLN9227 (4436€),
including PLN2432 (1169€) of direct costs. The regression
model incorporating complications, insulin treatment and man-
aging physicians’ specialty predicted direct costs associated with
diabetes best. Estimates were statistically signiﬁcant at p-level
0.05 and consistent with domain knowledge. Diabetologists’
patients generated lower mean direct treatment costs (PLN2140;
1028€) when compared to GP’s (PLN 2920; 1403€) for patients
of similar clinical characteristic. Controlling for case-mix dia-
betologists were more likely to increase drug cost balanced by
higher savings resulting from hospitalizations cost. CONCLU-
SIONS: Economic impact of diabetes type-2 is highly determined
by complications, insulin treatment and managing physicians’
specialty. Specialists (diabetologists) produce savings in direct
treatment costs which result from effective disease control with
drugs.
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OBJECTIVES: The installation of disease management programs
(DMP) is accompanied by expectations of high gains in health
and savings. This study estimates the potential gains of a DMP
for patients with type-2-diabetes for Germany under real life
conditions. METHODS: Representative data from the Germany
National Health Survey contained 307 subjects with type-2-dia-
betes, covering demographics, medical history, risk factors, and
treatment. Estimates for the risk to suffer from different com-
plications in the next ten years under given risk factor proﬁles
have been calculated using a validated prognosis model (Mel-
libase). Alternative risks have been calculated under the assump-
tion that in a DMP patients will reach individual risk factor levels
depending on their actual levels. Furthermore, assumptions have
been made for the patients’ persistence on a DMP scheme over
a 10-year period. Monetary savings for avoided complications
have been calculated using claims data of a German sickness
fund. RESULTS: In Germany there are 3.0 million patients with
known type-2-diabetes. Within the next ten years 18.9% of them
will suffer from a ﬁrst myocardial infarction, 19.2% from a ﬁrst
stroke. This will result in an average number of MIs of 56,000
and 57,000 strokes per year. About 2300MIs and 2000 strokes
are estimated to be avoided per year. Savings from avoided com-
plications will be approximately 120 million Euros per year. It
is estimated that the costs to run a DMP will exceed these
savings. CONCLUSIONS: Predicted health beneﬁts from a DMP
addressing all Type-2-diabetics are moderate in the actual
German health care system. Risk stratiﬁcation driven by prog-
nostic modeling is likely to improve this balance, if implemented.
Finally, the results underline that DMPs as other health 
technologies, need to be evaluated before their broad 
implementation.
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OBJECTIVES: In Ukraine, 800,000 Type-2 diabetic patients reg-
istered. Treatment state costs type 2 diabetes in Ukraine amount
to more than 36 billion GRN (1 Euro = 6.2GRN) per year,
mainly because of related complications. These complications
should be reduced at least by one-third by treating accordinng
to current guidelines. METHODS: The European Diabetes
Policy Group guidelines were applied to deﬁne the optimal
therapy regarding blood glucose, lipids and blood pressure.
Costs of guideline-related medication (antidiabetic drugs) and
costs of additional outpatient treatmant were calculated using
ofﬁcial tariffs. RESULTS: Guideline treatment would induce
1300GRN cost per patient for additional medication and out-
patient treatment. The phisicians prescribed glibenclamid
(maninil) 45% patients, metformin -18%, combined therapy 
-15%, insulin -22%. CONCLUSIONS: Treatment of patients
with type-2 diabetes according to the guidelines makes a huge
investment necessary. Assuming optimal treatment could prevent
25% diabetes-related complications and potential cost savings of
GRN 2 billion.
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